Korro Bio's Drug Trial Fails, Company Restructures

Korro Bios stock plummeted by 80% after disappointing clinical trial results for their Alpha-one Antitrypsin Deficiency drug, KRRO-one-ten. The drug only increased protein levels by 2 micromolars, far below the protective 11 micromolars. The company is now shifting focus to a new drug candidate and has announced a new drug for hyperammonemia. Korro Bio is undergoing a major restructuring, reducing its workforce by one-third, to extend its financial resources.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.